UPDATE: Wolfe Research Starts Acceleron Pharma (XLRN) at Outperform, Top Pick

March 11, 2021 4:55 PM EST
Get Alerts XLRN Hot Sheet
Price: $123.03 --0%

Rating Summary:
    17 Buy, 4 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 16 | Down: 10 | New: 9
Trade Now! 
Join SI Premium – FREE
(Updated - March 11, 2021 4:56 PM EST)

Wolfe Research analyst Akash Tewari initiates coverage on Acceleron Pharma (NASDAQ: XLRN) with a Outperform rating and a price target of $200.00.

The analyst comments "We think XLRN still has a lot of room to run here based on our opinion that pipeline drug Sotatercept will HIT in it’s phase 3 PAH trial given the good phase 2 data and a handful of “smart” trial tweaks mgt is making in ph3 to tip the scales in their favor. We believe this drug could become the first disease modifying PAH treatment and become the backbone of combination therapy, generating over $2B in sales."

For an analyst ratings summary and ratings history on Acceleron Pharma click here. For more ratings news on Acceleron Pharma click here.

Shares of Acceleron Pharma closed at $128.94 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Hot Comments, Hot New Coverage, New Coverage